Zula Therapeutics

What Zula Therapeutics does

Zula Therapeutics is a biopharmaceutical company founded in 2024 as a Delaware public benefit corporation spun out from Courage Therapeutics. It is developing metreleptin, a recombinant form of human leptin, as hormone replacement therapy for patients with anorexia nervosa, particularly those with severe leptin deficiency. The lead program is in pre-IND and manufacturing development, and the company has no commercial product or disclosed revenue.

Zula’s lead scientific hypothesis is that weight loss can produce hypoleptinemia, or low leptin, which contributes to the psychiatric and metabolic effects that reinforce food avoidance. Metreleptin is intended to replace leptin and normalize signaling, while the company reports issued method-of-use patent coverage through 2045. Zula is also seeking to develop a more affordable metreleptin version for anorexia nervosa, contrasting with the approximately $1.2 million annual cost cited for Myalept in lipodystrophy.

The intended business model is prescription pharmaceutical sales after regulatory approval. As a pre-revenue developer, Zula is using its public-benefit structure to attract impact investors and states that patient access and affordability are corporate priorities. (Primary evidence:.)

Name

Zula Therapeutics

Legal name

Zula Therapeutics, Inc.

Website

https://zulatx.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

Zula Therapeutics is a pre-IND biopharmaceutical company developing metreleptin-based leptin replacement therapy for patients with anorexia nervosa, with future commercialization expected through sales of a prescription product after regulatory approval. (Primary evidence:.)

Ownership category

akta.pro rank

Product category

Eating Disorder Therapeutics / Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

akta.pro secondary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Anorexia nervosa therapeutics
• Hormone replacement therapy
• Metreleptin development
• Eating disorder biopharmaceuticals
• Leptin receptor agonists

Headquarters

HQ city

Pittsfield

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Once approved, Zula will commercialize metreleptin as a prescription medication for anorexia nervosa. The company is developing a more affordable version of metreleptin specifically for this indication, addressing the current ~$1.2M/year cost of Myalept for lipodystrophy.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Zula Therapeutics is developing metreleptin, a recombinant form of human leptin, as a hormone replacement therapy for anorexia nervosa. The therapy is designed to address severe leptin deficiency (hypoleptinemia) caused by starvation, with the goal of becoming the first FDA-approved medication for the condition. The company is also working on improved metreleptin formulations with enhanced stability, optimized dosing, and extended-release potential.

Product overview

Zula Therapeutics is developing metreleptin as a breakthrough hormone replacement therapy for anorexia nervosa. The core product is metreleptin, a recombinant form of human leptin that addresses the hypoleptinemia (leptin deficiency) that occurs in anorexia nervosa patients. The company is also developing improved formulations of metreleptin with enhanced stability, optimized dosing, and extended release capabilities. Metreleptin is not yet FDA-approved for anorexia nervosa; it is currently approved as Myalept® for lipodystrophy. The company is pursuing regulatory approval through efficient pathways designed to make treatment accessible and affordable.

Differentiator

Problem solved

Functional benefit

Products and services

• Metreleptin for Anorexia Nervosa Recombinant human leptin (metreleptin) hormone replacement therapy intended to become the first FDA-approved medication for treating anorexia nervosa by addressing the neuropsychiatric effects of severe leptin deficiency (hypoleptinemia) in AN patients.

Quantifiable outcome

• Depression scores improved within days of treatment initiation
• +4 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• University of Duisburg-Essen (UDE)coreStrategic or Co-development Partner · 11 August 2026UDE researchers, led by Professor Johannes Hebebrand, identified leptin deficiency as an active driver of anorexia nervosa. Zula licenses the patents for metreleptin use in AN from UDE. Professor Hebebrand serves as Scientific Advisor and co-inventor. The collaboration enables Zula to advance clinical development based on UDE's groundbreaking research.
• Mount Sinai's Center of Excellence in Eating and Weight DisorderscoreStrategic or Co-development PartnerCollaboration with Icahn School of Medicine at Mount Sinai, led by Dr. Tom Hildebrandt, PsyD. Mount Sinai leads the design and execution of clinical studies of leptin replacement in severe anorexia nervosa. The center is also leading a philanthropic fundraising campaign in support of this work. Mount Sinai's outpatient care model has shown a 70-80% success rate at halting recidivism.
• University of ZurichcoreStrategic or Co-development PartnerResearch collaboration with University of Zurich where early studies of metreleptin in anorexia nervosa patients showed promising results. Professor Gabriella Milos, MD, of University Hospital Zurich, is a co-inventor on the patent and leads an investigator-initiated randomized controlled trial of metreleptin (ClinicalTrials.gov NCT06305182).
• Courage TherapeuticscoreOthersZula Therapeutics was spun out from Courage Therapeutics as a Public Benefit Corporation. Courage holds an equity stake in Zula and maintains a collaborative relationship. This structure allows Courage to advance its melanocortin peptide programs through conventional venture funding while Zula focuses on metreleptin development with impact investors.
• National Eating Disorders Association (NEDA)minorGTM or Marketing PartnerNEDA CEO Jessica Scheer provided a quote supporting Zula's research as a scientific breakthrough for the eating disorders community. NEDA educates the public on eating disorders and their biological basis. Zula works with patient advocacy organizations to build awareness and support for clinical trials.

Scale indicators6 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Sage Therapeutics (Biogen): CNS therapeutics developer (Zurzuvae/zuranolone) acquired by Biogen. Another relevant precedent for the development-to-acquisition trajectory available to a single-asset CNS biotech with a differentiated mechanism and unmet need.
• Intra-Cellular Therapies (Johnson & Johnson): CNS-focused developer (Caplyta/lumateperone) acquired by J&J. Comparable as a precedent for a CNS-focused biotech achieving FDA approval in a psychiatric indication and being acquired by a large pharma seeking CNS commercial scale.
• Regeneron Pharmaceuticals: Large-cap biotech with deep R&D in leptin/leptin-receptor biology and adjacent metabolic pathways. Functions as a broad incumbent in the mechanistic space Zula is commercializing, with far greater resources to enter AN should the market validate.
• Acadia Pharmaceuticals: Commercial-stage CNS specialty pharma with established psychiatric sales infrastructure. Represents the type of strategic acquirer or comparable commercial-stage counterpart Zula could become or partner with as it approaches FDA approval in an underserved psychiatric indication.

Direct peers

• Chiesi Farmaceutici (Amryt Pharma): Chiesi acquired Amryt Pharma, which markets Myalept (metreleptin) for lipodystrophy — the same recombinant leptin molecule Zula is developing. Chiesi controls the only commercial supply of metreleptin today and is the most direct peer on both asset and mechanism.
• Rhythm Pharmaceuticals: Commercial-stage rare-disease biotech focused on melanocortin-4 receptor pathway hyperphagic/obesity disorders. Most directly comparable on the underlying biology (melanocortin pathway) and on the rare-endocrine commercial model — Zula's parent Courage Therapeutics is also pursuing melanocortin peptides.
• Soleno Therapeutics: Small-cap clinical-stage biotech developing therapeutics for rare metabolic/neurodevelopmental disorders (Prader-Willi syndrome). Comparable in scale, stage, and orphan/metabolic disease focus to Zula, with a similar single-asset risk profile and pivotal-stage execution story.
• Tonix Pharmaceuticals: Clinical-stage CNS-focused biopharma developing therapeutics across psychiatry and neurology. Comparable in stage (pre-commercial/early-commercial), single- to few-asset structure, and reliance on pivotal CNS readouts for valuation inflection.
• Compass Pathways: Clinical-stage biotech developing psychiatric therapeutics (psilocybin-based therapies) for treatment-resistant depression and other mental health indications. Comparable stage, regulatory complexity in psychiatry, and mission-driven positioning.

Emerging players

• Passage Bio: Early-stage clinical biotech focused on rare neurological disorders. Comparable in stage, small team footprint, and reliance on academic-licensed IP — a relevant peer for what Zula looks like at its current stage before IND.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zula-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zula Therapeutics